RNS Number : 9616V
Microsaic Systems plc
12 April 2019

12 April 2019

Microsaic Systems plc

("Microsaic" or the "Company")

Notice of Annual General Meeting and Posting of Annual Report


Microsaic Systems plc (AIM: MSYS), the developer of point of need mass spectrometry instruments, is pleased to announce that its Annual General Meeting will be held at 11.00 a.m. on 14 May 2019 at the offices of N+1 Singer, One Bartholomew Lane, London, EC2N 2AX. The Annual Report (including the Notice of Annual General Meeting) and the Form of Proxy will be posted to shareholders today. The Annual Report is available on the Company's website at http://www.microsaic.com/investors/documents/.






Microsaic Systems plc

Glenn Tracey, CEO

Bevan Metcalf, FD

+44 (0) 1483 751 577


N+1 Singer (Nominated Adviser & Broker)

Shaun Dobson (Corporate Finance)

Tom Salvesen (Corporate Broking)



+44 (0)20 7496 3000

IFC Advisory Ltd (Financial PR)

Graham Herring

Heather Armstrong

Florence Chandler

+44 (0)20 3934 6630



About Microsaic Systems

Microsaic Systems plc (AIM: MSYS) is a high technology company developing chip-based, bench-top and point-of-analysis mass spectrometry ("MS") instruments that are designed to improve the efficiency of pharmaceutical R&D and manufacturing. The Company is working with established global life science companies to co-develop new solutions to improve productivity in the development of small molecule and novel biologic (peptides, antibodies) medicines. MS is a powerful method of analysis to enable earlier decision making relating to product identification, purity and bioactivity, and is the analytical technique of choice for biochemists across many industry sectors.


Microsaic's core product, the 4500 MiD®, is a robust and compact MS system, retaining the functionality of larger conventional MS systems, is easier to use by non-specialists, consumes less energy and has lower running costs. For more information, please go to www.microsaic.com.  



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.